Financials data is unavailable for this security.
View more
Year on year Pliant Therapeutics Inc 's revenues fell -83.69% from 9.69m to 1.58m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 123.32m to a larger loss of 161.34m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -40.90% |
---|---|
Return on equity | -47.52% |
Return on investment | -43.90% |
More ▼
Cash flow in USDView more
In 2023, Pliant Therapeutics Inc increased its cash reserves by 92.13%, or 31.03m. Cash Flow from Financing totalled 274.41m or 17,367.41% of revenues. In addition the company used 116.36m for operations while cash used for investing totalled 127.01m.
Cash flow per share | -3.31 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 5.68 |
---|---|
Tangible book value per share | 5.68 |
More ▼
Balance sheet in USDView more
Current ratio | 10.26 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0872 |
---|---|
Total debt/total capital | 0.0802 |
More ▼